Oyster Point Pharma, Inc(NASDAQ:OYST) 
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor ago...
Website: http://www.oysterpointrx.com
Founded: 2015
IPO Price: $16 (Oct 31, 2019)
Full Time Employees: 62 (May 2021)
CEO: Jeffrey A. Nau
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2022-07-07
P
O 4.50
H 4.63
L 4.20
C 4.58
V 162,727
10EMA 4.58
20EMA 4.58
60EMA 4.58
120EMA 4.58
250EMA 4.58